Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291384 | 0.83 | HTR2C (0.44) | HTR2CHTR2AHTR2BKCNH2GSK3B | |
| SCHEMBL20037535 | 0.82 | HTR2C (0.41) | HTR2CHTR2AHTR2BKCNH2GSK3B | |
| SCHEMBL30609645 | 0.82 | BPTF (0.55) | HTR2CHTR2AHTR2B | |
| SCHEMBL22489453 | 0.82 | BPTF (0.55) | HTR2CHTR2AHTR2B | |
| SCHEMBL18291427 | 0.82 | HTR2C (0.41) | HTR2CHTR2AHTR2BKCNH2GSK3B | |
| SCHEMBL17884816 | 0.82 | BPTF (0.55) | HTR2CHTR2AHTR2B | |
| SCHEMBL20249160 | 0.79 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2GSK3B | |
| SCHEMBL20249167 | 0.79 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2GSK3B | |
| SCHEMBL18291359 | 0.78 | IRAK4 (0.37) | HTR2CHTR2AHTR2B | |
| SCHEMBL20142347 | 0.76 | HTR2C (0.43) | HTR2CHTR2AHTR2BGSK3BLATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HTR2C 2627/4885HTR2A 3588/4885HTR2B 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.